Details Basic Details Date Sunday, August 25, 2019 Type Presentation Medical Product sodium-glucose cotransporter-2 (SGLT-2) inhibitor Health Outcome(s) diabetic ketoacidosis Materials Analysis of SGLT2 Inhibitor Use in Patients with Type-1 Diabetes Mellitus and Rates of Diabetic Ketoacidosis Additional Information Information Host 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Related Assessment(s) Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24‐28, 2019 Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis SGLT-2 Inhibitor Use and Incidence of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus Sentinel Drug Study: Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors & Diabetic Ketoacidosis (DKA) and Use in Type 1 Diabetes Mellitus (T1DM) Contributors Presenter(s) Christian Hampp